Anxiety Disorder

[키워드] 1:1 addition addressed administration Adult patients adverse event adverse events AEs age all-cause hospitalization Antibody Response Anxiety Anxiety Disorder ARMS association Biomarker blinded Blinding Blood BMI capture Care changes changes in Characteristics clinical trial concentrations concomitant medications conducted Contact Course COVID-19 COVID-19 infection COVID-19-related symptoms criteria death deleting Demographic variables diabetes Diabetes Mellitus disease dissemination double-blind Effect element enrolment enzyme EudraCT evaluate exclusion expected exploratory exploratory endpoint Exploratory endpoints female Formulation GAD-7 Generalized Generalized Anxiety Disorder Genetic variation HCQ Health care HLA haplotypes hospital Hospitalization hospitalizations Hydroxychloroquine Hypothesis identify include Inclusion independent individual Infection information intensive care unit lactation masking mental health Meta-analysis Mortality Nasopharyngeal swab nasopharyngeal swab sample Nasopharyngeal swab samples number number of deaths objective onset of symptom open care outcome Outpatient outpatients parallel-group participant Patient patient data PCR test PCR testing PCR-confirmed Placebo placebo-controlled post-hoc predict Pregnancy presenting primary care primary endpoint protocol public health public health care randomised randomised controlled trial randomization list Randomized Randomly receive recruitment reduce Registered Regulation repeated reported respiratory respiratory distress respiratory rate response risk room air SAEs Sample size SARS-CoV-2 SARS-CoV-2 PCR test SARS-CoV-2 viral shedding Satakunta secondary endpoint Secondary endpoints Secondary objectives serious AE serum Seven severe pneumonia severity specific treatment status study participant Study participants study population Study protocol subgroup analysis subject supplementary material Suspected Symptom Symptoms technology test result therapeutic potential Tolerability treated Treatment treatment allocation treatment arm Trial Trial registration twice a day type 1 or type 2 Uppsala variable Viral was performed website Well-being
[DOI] 10.1186/s13063-020-04989-6 PMC 바로가기 [Article Type] Letter